Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 2A clinical study titled A Phase 2A Multicenter, Observer-Blinded, Randomized 2 Arm Study to Investigate Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Aztreonam-Avibactam ± Metronidazole Compared to Best Available Therapy (BAT) in Pediatric Participants 9 Months to Less Than 18 Years of Age with Serious Gram-Negative Bacterial Infections Including Complicated Intra-Abdominal Infection. The study aims to evaluate the pharmacokinetics, safety, and efficacy of Aztreonam and Avibactam in pediatric patients with serious gram-negative infections, highlighting its significance in addressing antibiotic resistance in this vulnerable population.
This study tests the combination of Aztreonam (ATM) and Avibactam (AVI), designed to treat resistant gram-negative bacterial infections. The intervention is administered intravenously and aims to provide an effective treatment option for serious infections in children.
The study follows a randomized, open-label, parallel design with a single-blinded observer. Participants are randomly allocated to receive either the experimental ATM-AVI treatment or the best available therapy (BAT). The primary purpose is treatment-focused, with the study assessing pharmacokinetics and safety as primary endpoints.
The study began on April 18, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The clinical study’s update could influence Pfizer’s stock performance and investor sentiment positively, given the potential breakthrough in treating resistant infections in children. This development could also impact the competitive landscape, as other pharmaceutical companies may need to accelerate their efforts in similar research areas.
The study is ongoing, with further details available on the ClinicalTrials portal.